Select publications

Publications discussed by Dr Cunningham

Benson AB et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2003;Abstract 975.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.

Giantonio BJ et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Proc ASCO 2003;Abstract 1024.

Harba A et al. Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). Proc ASCO 2003;Abstract 1335.

Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.

Rao S et al. Capecitabine and mitomycin-C (MMC) shows promising activity as a 3rd line agent in patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan. Proc ASCO 2003;Abstract 1286.

Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR Study. J Clin Oncol 2004;[Epub ahead of print] J Clin Oncol. 2004 Jan 15;22(2):229-37. Epub 2003 Dec 02. Abstract.

Twelves C et al. Improved safety results of a ph III trial of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT Study). Proc ASCO 2003;Abstract 1182.

Watkins D et al. Capecitabine and mitomycin-C: An active low toxicity first line therapy in metastatic colorectal cancer (MCRC). Proc ASCO 2003;Abstract 1109.